New agents in renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology
• Medical Research

Background:

• Limited treatment options existed for metastatic renal cell carcinoma (mRCC) before 2005.
• The introduction of targeted agents like sorafenib and sunitinib marked a turning point in advanced renal cell carcinoma treatment.
• Recent FDA approvals have expanded the therapeutic landscape for mRCC.

Purpose of the Study:

• To review the evolution and development of new targeted agents for mRCC.
• To examine the adverse event profiles of pazopanib, axitinib, everolimus, and temsirolimus.
• To discuss future directions and novel agents in clinical trials for mRCC.

Main Methods:

• Literature review of investigational agents for mRCC.
• Analysis of clinical trial data for targeted therapies.
• Examination of FDA-approved agents and their pathways.

Main Results:

• Significant proliferation of targeted agents since 2005, focusing on VEGF-TKIs and mTOR inhibitors.
• Four new agents approved by the FDA for mRCC treatment.
• Ongoing exploration of novel agents in clinical trials for these targeted pathways.

Conclusions:

• The treatment paradigm for mRCC has dramatically shifted towards targeted therapies.
• Understanding the efficacy, safety, and future potential of these agents is crucial for patient care.
• Continued research into novel agents promises further advancements in mRCC management.